Philadelphia, Pennsylvania


Sheller, P.C.

Heartburn Drugs Nexium, Prilosec, Prevacid Linked to Kidney Failure

Popular prescription heartburn medications may cause long-term kidney damage, according to a study published in JAMA Internal Medicine. Nexium, Prevacid and Prilosec, are in a class of drugs called proton pump inhibtors (PPIs) that are used to treat acid reflux […]

Sheller, P.C.

Zofran Lawsuits: New Study Claims Drug Not Linked to Birth Defects

Zofran (ondansetron) has been under fire in past months with two studies suggesting a link between the drug and birth defects. In fact, the drugmaker, GlaxoSmithKline (GSK), is facing lawsuits stemming from claims that exposure to the drug Zofran during […]

Sheller, P.C.

Invokana Linked to Increased Risk of Diabetic Ketoacidosis in New Trial

The findings of a new clinical trial suggest Invokana (canagliflozin), used for treating Type 2 diabetes may also help to treat people with Type 1 diabetes by controlling blood sugar. But, it may increase the risk of diabetic ketoacidosis (DKA) […]

Sheller, P.C.

$15.5 Million Settlement in Risperdal Failure to Warn, Off-Label Marketing Lawsuit

A settlement of $15.5 million was reached between the Kentucky Attorney General and Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) regarding the drug Risperdal, used widely to treat schizophrenia. The suit was originally filed with allegations that the drug […]

Sheller, P.C.

Three of Four Pennsylvania Risperdal Lawsuits Favor Plaintiffs

Janssen Pharmaceuticals (a Johnson & Johnson subsidiary) is currently facing at least 1,600 Risperdal cases pending in Philadelphia court. A prescription medication used to treat bipolar disorder and schizophrenia, Risperdal is at the center of numerous lawsuits on behalf of male […]

Sheller, P.C.

Is a Xarelto Bleeding Antidote in Sight?

Portola Pharmaceuticals has designed a treatment to reverse the effects of blood thinners Xarelto and Eliquis. The anti-anticoagulant came through in a pair of Phase III trials and is poised for final FDA submission. The treatment, andexanet alfa, works as […]

Sheller, P.C.

FDA Updates Invokana Label, Includes Stronger Warnings

The U.S. Food and Drug Administration (FDA) has strengthened the warning for the Type II diabetes drug canagliflozin (Invokana, Invokamet) to include the increased risk of bone fractures and added new information about decreased bone mineral density. In 2013, Invokana […]

Sheller, P.C.

Xarelto Sales Spike Linked to Groups, Doc Paid by Big Pharma

In an article co-authored by writers from the Milwaukee Journal Sentinel and Medpage Today, a closer look is taken at the concerns surrounding the influence of pharmaceutical companies on medical professionals who prescribe their medicines. However, it’s not just doctors […]

Sheller, P.C.

Money in Medicine: Medtronic Payments to Infuse Doctors Continues

Medical device giant, Medtronic, continues to pay millions to doctors who research on a controversial spinal product that has come into question, according to new federal data. In 2014, Medtronic Sofamor Danek, paid $60.7 million in royalties to 79 doctors […]

Jamie Sheller

FDA Warns Noven’s ADHD Patch Can Cause Skin Disfiguration

The U.S. Administration on Thursday said Noven Pharmaceuticals Inc.’s patch used to treat attention deficit hyperactivity disorder could cause permanent loss of skin color. Noven’s methylphenidate transdermal system, sold as the Daytrana Patch, can cause the discolorations, which are disfiguring […]